BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18355919)

  • 41. Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Nishii K; Sakakura M; Tsukada T; Ryuu H; Katayama N
    Int J Hematol; 2007 Apr; 85(3):273-4. PubMed ID: 17483068
    [No Abstract]   [Full Text] [Related]  

  • 42. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
    Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
    Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
    Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
    Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The role of imatinib in the treatment of acute lymphoid leukemias].
    Poros A; Lovas N
    Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
    Viniou NA; Vassilakopoulos TP; Giakoumi X; Mantzouranis M; Pangalis GA
    Eur J Haematol; 2004 Jan; 72(1):58-60. PubMed ID: 14962264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
    Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
    Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G; Cortes JE
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
    Goldberg SL; Madan RA; Rowley SD; Pecora AL; Hsu JW; Tantravahi R
    Blood; 2003 Jan; 101(2):781. PubMed ID: 12509385
    [No Abstract]   [Full Text] [Related]  

  • 53. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fielding AK
    Blood; 2010 Nov; 116(18):3409-17. PubMed ID: 20656928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
    Schultz KR; Carroll A; Heerema NA; Bowman WP; Aledo A; Slayton WB; Sather H; Devidas M; Zheng HW; Davies SM; Gaynon PS; Trigg M; Rutledge R; Jorstad D; Winick N; Borowitz MJ; Hunger SP; Carroll WL; Camitta B;
    Leukemia; 2014 Jul; 28(7):1467-71. PubMed ID: 24441288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
    Li S
    Leuk Lymphoma; 2008 Jan; 49(1):19-26. PubMed ID: 18203007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.
    Drummond MW; Marin D; Clark RE; Byrne JL; Holyoake TL; Lennard A;
    Br J Haematol; 2003 Nov; 123(3):479-83. PubMed ID: 14617010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
    Cojbasić I; Macukanović-Golubović L
    Vojnosanit Pregl; 2011 Nov; 68(11):911-6. PubMed ID: 22191306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.